Literature DB >> 15650371

Isoniazid resistance and the future of drug-resistant tuberculosis.

Ted Cohen1, Mercedes C Becerra, Megan B Murray.   

Abstract

Bacterial chromosomal mutations that confer antibiotic resistance often have deleterious effects that impose costs on reproductive fitness. This observation has led to the generalization that in the absence of the selection pressure exerted through treatment, the frequency of resistance will decrease. This model implies that the prudent use of antibiotics will eventually result in a decline in the prevalence of drug resistance. Recent work, however, suggests that some resistance-conferring mutations may not significantly impair fitness and that others may be accompanied by compensatory mutations that restore the organisms' reproductive potential. Thus drug resistance, once introduced, may persist unless specific measures are implemented to target prevalent drug-resistant cases. Here we present ecological evidence to support the hypothesis that mutations at the 315 position of katG confer isoniazid resistance for Mycobacterium tuberculosis without diminishing virulence or transmissibility.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15650371      PMCID: PMC2652757          DOI: 10.1089/mdr.2004.10.280

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  31 in total

1.  Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru.

Authors:  P Escalante; S Ramaswamy; H Sanabria; H Soini; X Pan; O Valiente-Castillo; J M Musser
Journal:  Tuber Lung Dis       Date:  1998

Review 2.  The genetics and biochemistry of isoniazid resistance in mycobacterium tuberculosis.

Authors:  R A Slayden; C E Barry
Journal:  Microbes Infect       Date:  2000-05       Impact factor: 2.700

3.  Strain families of Mycobacterium tuberculosis.

Authors:  Paul D van Helden; Robin M Warren; Thomas C Victor; Gian van der Spuy; Madalene Richardson; Eileen Hoal-van Helden
Journal:  Trends Microbiol       Date:  2002-04       Impact factor: 17.079

4.  Molecular analysis of rifampin and isoniazid resistance of Mycobacterium tuberculosis clinical isolates in Seville, Spain.

Authors:  N González; M J Torres; J Aznar; J C Palomares
Journal:  Tuber Lung Dis       Date:  1999

5.  Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

Authors:  M A Espinal; A Laszlo; L Simonsen; F Boulahbal; S J Kim; A Reniero; S Hoffner; H L Rieder; N Binkin; C Dye; R Williams; M C Raviglione
Journal:  N Engl J Med       Date:  2001-04-26       Impact factor: 91.245

6.  Evaluation of katG codon 315 mutations among isoniazid sensitive and resistant mycobacterium tuberculosis isolates from Thailand.

Authors:  P Imwidthaya; K Mieskes; S Rienthong
Journal:  J Med Assoc Thai       Date:  2001-06

7.  Neighborhood poverty and the resurgence of tuberculosis in New York City, 1984-1992.

Authors:  R G Barr; A V Diez-Roux; C A Knirsch; A Pablos-Méndez
Journal:  Am J Public Health       Date:  2001-09       Impact factor: 9.308

8.  Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa.

Authors:  P Kiepiela; K S Bishop; A N Smith; L Roux; D F York
Journal:  Tuber Lung Dis       Date:  2000

9.  Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands.

Authors:  D van Soolingen; P E de Haas; H R van Doorn; E Kuijper; H Rinder; M W Borgdorff
Journal:  J Infect Dis       Date:  2000-10-26       Impact factor: 5.226

10.  Rifampin and isoniazid resistance associated mutations in Mycobacterium tuberculosis clinical isolates in Seville, Spain.

Authors:  M J Torres; A Criado; N Gónzalez; J C Palomares; J Aznar
Journal:  Int J Tuberc Lung Dis       Date:  2002-02       Impact factor: 2.373

View more
  18 in total

Review 1.  Antibiotic resistance and its cost: is it possible to reverse resistance?

Authors:  Dan I Andersson; Diarmaid Hughes
Journal:  Nat Rev Microbiol       Date:  2010-03-08       Impact factor: 60.633

2.  Nε- and O-Acetylation in Mycobacterium tuberculosis Lineage 7 and Lineage 4 Strains: Proteins Involved in Bioenergetics, Virulence, and Antimicrobial Resistance Are Acetylated.

Authors:  Alemayehu Godana Birhanu; Solomon Abebe Yimer; Carol Holm-Hansen; Gunnstein Norheim; Abraham Aseffa; Markos Abebe; Tone Tønjum
Journal:  J Proteome Res       Date:  2017-10-04       Impact factor: 4.466

Review 3.  Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis.

Authors:  S Borrell; S Gagneux
Journal:  Clin Microbiol Infect       Date:  2011-06       Impact factor: 8.067

Review 4.  Isoniazid-resistant tuberculosis: a cause for concern?

Authors:  H R Stagg; M C Lipman; T D McHugh; H E Jenkins
Journal:  Int J Tuberc Lung Dis       Date:  2017-02-01       Impact factor: 2.373

Review 5.  Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy.

Authors:  Digby F Warner; Valerie Mizrahi
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

Review 6.  Multidrug-resistant tuberculosis drug susceptibility and molecular diagnostic testing.

Authors:  Ameeta S Kalokhe; Majid Shafiq; James C Lee; Susan M Ray; Yun F Wang; Beverly Metchock; Albert M Anderson; Minh Ly T Nguyen
Journal:  Am J Med Sci       Date:  2013-02       Impact factor: 2.378

7.  Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis.

Authors:  Adithya Cattamanchi; Raymund B Dantes; John Z Metcalfe; Leah G Jarlsberg; Jennifer Grinsdale; L Masae Kawamura; Dennis Osmond; Philip C Hopewell; Payam Nahid
Journal:  Clin Infect Dis       Date:  2009-01-15       Impact factor: 9.079

8.  Spontaneous emergence of multiple drug resistance in tuberculosis before and during therapy.

Authors:  Caroline Colijn; Ted Cohen; Ayalvadi Ganesh; Megan Murray
Journal:  PLoS One       Date:  2011-03-30       Impact factor: 3.240

9.  Correlations of mutations in katG, oxyR-ahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America.

Authors:  Elis R Dalla Costa; Marta O Ribeiro; Márcia S N Silva; Liane S Arnold; Diana C Rostirolla; Patricia I Cafrune; Roger C Espinoza; Moises Palaci; Maria A Telles; Viviana Ritacco; Philip N Suffys; Maria L Lopes; Creuza L Campelo; Silvana S Miranda; Kristin Kremer; Pedro E Almeida da Silva; Leila de Souza Fonseca; John L Ho; Afrânio L Kritski; Maria L R Rossetti
Journal:  BMC Microbiol       Date:  2009-02-19       Impact factor: 3.605

10.  Activity of trifluoperazine against replicating, non-replicating and drug resistant M. tuberculosis.

Authors:  Meeta J Advani; Imran Siddiqui; Pawan Sharma; Hemalatha Reddy
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.